Plasma homocysteine levels and risk of Alzheimer disease

Neurology

Volumn 62, Issue 11, 2004, Pages 1972-1976

  Luchsinger, J A ^a,c   Tang, M X ^a   Shea, S ^a,c   Miller, J ^d   Green, R ^d   Mayeux, Richard ^a,b,c,e  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Columbia Univ Coll of Phys/Surgs ^*  (United States)

^c University of California ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; FEMALE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEMORY; PREVALENCE; PRIORITY JOURNAL;

EID: 2942538501     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000129504.60409.88     Document Type: Article

References (30)

1. Hake AM, Scherer P. On the brink of the pandemic: epidemiology and risk factors for Alzheimer's. Summaries from the World Alzheimer's Congress 2000; July 9-18, 2000, Washington, DC. Available at: http:// www.medscape.com/Medscape/CNO/2000/WAC/Story.cfm?story_id=1523.
2. Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk of congestive heart failure in adults without prior myocardial infarction. JAMA 2003;289:1251-1257.
3. Tanne D, Haim M, Godbourt U, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003;34:632-636.
4. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
5. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 2002;58:1471-1475.
6. LeBoeuf R. Homocysteine and Alzheimer's disease. J Am Diet Assoc 2003;103:304-307.
7. Tang M, Stern Y, Marder K, et al. The ApoE-ε4 allele and the risk of Alzheimer's disease among African Americans, whites, and Hispanics. JAMA 1998;279:751-755.
8. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population, I: development of a neuropsychological paradigm and quantified correction for education. Arch Neurol 1992;49:453-460.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). Washington, DC: American Psychiatric Association, 1994;143-147.
10. Hughes CP, Berg L, Danzinger W, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
12. World Health Organization. The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research. Geneva, Switzerland: World Health Organization, 1993;36-40.
13. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974;24:1019-1025.
14. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Philadelphia: Lea & Febiger, 1983.
15. Benton A, ed. FAS test. Victoria, BC: University of Victoria, 1967.
16. Wechsler D. Wechsler Adult Intelligence Scale-revised. New York, NY: The Psychological Corporation, 1981.
17. Mattis S. Mental status examination for organic mental syndrome in the elderly patient. In Bellak L, Karasu TB, eds. Geriatric psychiatry. New York, NY: Grune and Stratton, 1976.
18. Rosen W. The Rosen Drawing Test. Bronx, NY: Veterans Administration Medical Center.
19. Benton AL. The Benton Visual Retention Test. New York, NY: The Psychological Corporation, 1955.
20. Gilfix BM, Blank DW, Rosenblatt DS. Novel reductant for determination of total plasma homocysteine. Clin Chem 1997;43:687-688.
21. El-Khairy L, Ueland PM, Refsum H, Graham I, Vollset SE. Plasma total cysteine as a risk factor for vascular disease. The European Concerted Action Project. Circulation 2001;103:2544-2549.
22. 1990 Census of population and housing: summary tape file 1, technical documentation (computer diskette). STF 1A database. Washington, DC: Bureau of the Census, 1991.
23. Hixson J, Vernier D. Restriction isotyping of human lipoprotein E by gene amplification and cleavage of HhAI. J Lipid Res 1991;31:545-548.
24. Nilsson K, Gustafson L, Faldt R, et al. Hyperhomocysteinemia-a common finding in a psychogeriatric population. Eur J Clin Invest 1996;26:853-859.
25. Rasmussen K, Moller J, Lyngbak M, Pedersen AM, Dybkjaer L. Age and gender specific reference intervals for total homocysteine and methyl-malonic acid in plasma before and after vitamin supplementation. Clin Chem 1996;42:630-636.
26. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: the Rotterdam scan study. Ann Neurol 2002;51:285-289.
27. Vermeer SE, Prinds ND, Den Heijer T, et al. Silent infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-1222.
28. den Heijer T, Vermeer SE, Clarke R, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003;126:170-175.
29. Riggs KM, Spiro A, Tucker K, Rush D. Relations of vitamin B-12, vitamin B6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996;63:306-314.
30. McCaddon A, Hudson P, Davies G, Hugues A, Williams JH, Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 2001;12:309-313.